BIOMAT Database Logo BIOMAT Database Logo

Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. 1996

H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Japan.

The mydriatic response to dilute tropicamide was studied in 25 Japanese patients with Alzheimer's disease (AD), 13 patients with non-AD neurological diseases (non-AD) and 11 normal elderly subjects (control). Although the changes in resting pupil diameter and area over baseline were significantly greater (p < 0.05) in AD patients than in non-AD patients and controls, there was considerable overlap between the three groups. The change in resting pupil area was significantly greater (p < 0.05) in AD patients homozygous for ApoE epsilon 4 than in AD patients heterozygous for or without this allele. Despite a limited sample size in the present study, our results indicate that the pupil dilation assay by tropicamide is not an effective diagnostic tool for AD, and it may be modulated by different gene dosage of ApoE epsilon 4.

UI MeSH Term Description Entries
D009184 Mydriatics Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. Cycloplegic,Cycloplegics,Mydriatic,Mydriatic Effect,Mydriatic Effects,Effect, Mydriatic,Effects, Mydriatic
D011680 Pupil The aperture in the iris through which light passes. Pupils
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D014331 Tropicamide One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic. Colircusi Tropicamida,Minims Tropicamide,Mydral,Mydriafair,Mydriaticum,Mydrum,N-Ethyl-N-(4-pyridylmethyl)tropamide,N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide,Ocu-Tropic,Tropicacyl,Tropicamide Faure,Tropicamide Minims,Tropicamide Monofree,Tropicamide Monohydrochloride, (R)-Isomer,Tropicamide Monohydrochloride, (S)-Isomer,Tropicamide, (+-)-Isomer,Tropicamide, (R)-Isomer,Tropicamide, (S)-Isomer,Ocu Tropic,OcuTropic
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
November 1993, Lancet (London, England),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
November 1993, Lancet (London, England),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
November 1993, Lancet (London, England),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
November 1993, Lancet (London, England),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
November 1993, Lancet (London, England),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E epsilon 4 allele and pupillary response to tropicamide.
May 1997, The American journal of psychiatry,
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Alzheimer's disease and the apolipoprotein E epsilon 4 allele.
July 1994, Israel journal of medical sciences,
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease.
January 1996, Genetic epidemiology,
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia.
January 1994, Dementia (Basel, Switzerland),
H Arai, and M Terajima, and T Nakagawa, and S Higuchi, and H Mochizuki, and H Sasaki
Apolipoprotein E-epsilon 4 allele doses in late-onset Alzheimer's disease.
October 1994, Annals of neurology,
Copied contents to your clipboard!